1-[3-[2-(dimethylamino)ethyl]-1-ethylindol-5-yl]-N-methylmethanesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[3-[2-(dimethylamino)ethyl]-1-ethylindol-5-yl]-N-methylmethanesulfonamide
• 化学式: C₁₆H₂₅N₃O₂S
• 分子量: 323.5
• InChiKey: RMUXBBOLRGSQQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Indole derivatives, their use as medicines and pharmaceutical compositions containing them
  申请人：GLAXO GROUP LIMITED

  公开号：EP0500086A1

  公开（公告）日：1992-08-26

  The invention relates to indoles of general formula (I): wherein R¹ represents a hydrogen atom or a C₁₋₆ alkyl or C₃₋₆ alkenyl group; R² represents a hydrogen atom, a C₁₋₃ alkyl or C₃₋₆ alkenyl group, an aryl or ar(C₁₋₄)alkylene group, or a C₅₋₇ cycloalkyl group; R³ represents a hydrogen atom or a C₁₋₃ alkyl group; R⁴ and R⁵, which may be the same of different, each represents a hydrogen atom or a C₁₋₃alkyl or 2-propenyl group, or R⁴ and R⁵ together form an aralkylidine group; R⁶ represents a C₁₋₆ alkyl or C₃₋₆alkenyl group and Alk represents an alkylene chain containing two or three carbons atoms which may be unsubstituted or substituted by not more than two C₁₋₃ alkyl groups, and physiologically acceptable salts and solvates (e.g. hydrates) thereof. Compounds of general formula (I) are useful in treating conditions associated with cephalic pain, in particular migraine.

  本发明涉及一般式（I）的吲哚化合物：其中R¹代表氢原子或C₁₋₆烷基或C₃₋₆烯基基团；R²代表氢原子，C₁₋₃烷基或C₃₋₆烯基基团，芳基或ar（C₁₋₄）烷基基团，或C₅₋₇环烷基；R³代表氢原子或C₁₋₃烷基基团；R⁴和R⁵，它们可以相同或不同，每个代表氢原子或C₁₋₃烷基或2-丙烯基基团，或R⁴和R⁵一起形成芳基烷基亚胺基团；R⁶代表C₁₋₆烷基或C₃₋₆烯基基团，Alk代表含有两个或三个碳原子的烷基链，可以未取代或被不超过两个C₁₋₃烷基基团取代，以及其生理上可接受的盐和溶剂（例如水合物）。一般式（I）的化合物对于治疗与头痛有关的疾病特别是偏头痛是有用的。
• Compounds that inhibit cholinesterase
  申请人：Rupniak Nadia M. J.

  公开号：US20080261950A1

  公开（公告）日：2008-10-23

  Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.
• US8101782B2
  申请人：——

  公开号：US8101782B2

  公开（公告）日：2012-01-24